Achaogen (NASDAQ:AKAO) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Saturday.
Several other research analysts have also recently weighed in on AKAO. ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. SunTrust Banks dropped their price objective on shares of Achaogen to $27.00 and set a “buy” rating for the company in a research report on Wednesday, January 3rd. Mizuho restated a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a research report on Wednesday, January 3rd. Zacks Investment Research cut shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Guggenheim restated a “buy” rating and issued a $14.00 price objective on shares of Achaogen in a research report on Wednesday, January 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.56.
AKAO stock opened at $13.39 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.83 and a quick ratio of 4.83. Achaogen has a fifty-two week low of $9.83 and a fifty-two week high of $27.49. The company has a market capitalization of $598.64, a P/E ratio of -4.22 and a beta of 1.04.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.21). Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. The company had revenue of $1.87 million during the quarter, compared to the consensus estimate of $1.18 million. sell-side analysts forecast that Achaogen will post -3.48 EPS for the current fiscal year.
In other Achaogen news, major shareholder Robert W. Duggan bought 20,000 shares of the stock in a transaction on Monday, April 2nd. The stock was purchased at an average price of $12.51 per share, with a total value of $250,200.00. Following the acquisition, the insider now owns 6,411,108 shares of the company’s stock, valued at $80,202,961.08. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Robert W. Duggan bought 47,361 shares of the stock in a transaction on Wednesday, April 4th. The shares were acquired at an average cost of $12.44 per share, with a total value of $589,170.84. Following the acquisition, the insider now directly owns 6,411,108 shares in the company, valued at approximately $79,754,183.52. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 810,717 shares of company stock valued at $8,739,717 and have sold 10,089 shares valued at $110,576. 8.36% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new stake in Achaogen during the 4th quarter worth $151,000. Clear Harbor Asset Management LLC acquired a new stake in Achaogen during the 4th quarter worth $177,000. Ellington Management Group LLC acquired a new stake in Achaogen during the 4th quarter worth $177,000. Tower Research Capital LLC TRC grew its holdings in shares of Achaogen by 375.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 14,725 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Achaogen in the 4th quarter valued at $260,000. 77.37% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/23/achaogen-akao-stock-rating-upgraded-by-bidaskclub.html.
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.